These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12126907)

  • 1. Early phase II trial of human rotavirus vaccine candidate RV3.
    Barnes GL; Lund JS; Mitchell SV; De Bruyn L; Piggford L; Smith AL; Furmedge J; Masendycz PJ; Bugg HC; Bogdanovic-Sakran N; Carlin JB; Bishop RF
    Vaccine; 2002 Jul; 20(23-24):2950-6. PubMed ID: 12126907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
    Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
    Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.
    Cowley D; Boniface K; Bogdanovic-Sakran N; Kirkwood CD; Bines JE
    Hum Vaccin Immunother; 2017 Aug; 13(8):1908-1915. PubMed ID: 28481726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
    Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD;
    Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.
    Cowley D; Pavlic D; Bogdanovic-Sakran N; Boniface K; Kirkwood CD; Bines JE
    Hum Vaccin Immunother; 2018; 14(8):2082-2087. PubMed ID: 29688121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.
    Bines JE; At Thobari J; Satria CD; Handley A; Watts E; Cowley D; Nirwati H; Ackland J; Standish J; Justice F; Byars G; Lee KJ; Barnes GL; Bachtiar NS; Viska Icanervilia A; Boniface K; Bogdanovic-Sakran N; Pavlic D; Bishop RF; Kirkwood CD; Buttery JP; Soenarto Y
    N Engl J Med; 2018 Feb; 378(8):719-730. PubMed ID: 29466164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand.
    Chen MY; Kirkwood CD; Bines J; Cowley D; Pavlic D; Lee KJ; Orsini F; Watts E; Barnes G; Danchin M
    Hum Vaccin Immunother; 2017 May; 13(5):1126-1135. PubMed ID: 28059609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.
    Witte D; Handley A; Jere KC; Bogandovic-Sakran N; Mpakiza A; Turner A; Pavlic D; Boniface K; Mandolo J; Ong DS; Bonnici R; Justice F; Bar-Zeev N; Iturriza-Gomara M; Ackland J; Donato CM; Cowley D; Barnes G; Cunliffe NA; Bines JE
    Lancet Infect Dis; 2022 May; 22(5):668-678. PubMed ID: 35065683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.
    Bhandari N; Sharma P; Taneja S; Kumar T; Rongsen-Chandola T; Appaiahgari MB; Mishra A; Singh S; Vrati S;
    J Infect Dis; 2009 Aug; 200(3):421-9. PubMed ID: 19545211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
    Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM
    Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
    Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
    Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.
    At Thobari J; Damayanti W; Haposan JH; Nirwati H; Iskandar K; Samad ; Fahmi J; Sari RM; Bachtiar NS; Watts E; Bines JE; Soenarto Y
    Vaccine; 2021 Jul; 39(33):4651-4658. PubMed ID: 34244006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate.
    Barnes GL; Lund JS; Adams L; Mora A; Mitchell SV; Caples A; Bishop RF
    J Paediatr Child Health; 1997 Aug; 33(4):300-4. PubMed ID: 9323616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal administration of rhesus rotavirus tetravalent vaccine.
    Vesikari T; Karvonen A; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
    Pediatr Infect Dis J; 2006 Feb; 25(2):118-22. PubMed ID: 16462287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.
    Kawamura N; Tokoeda Y; Oshima M; Okahata H; Tsutsumi H; Van Doorn LJ; Muto H; Smolenov I; Suryakiran PV; Han HH
    Vaccine; 2011 Aug; 29(37):6335-41. PubMed ID: 21640780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
    Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
    Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
    Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
    Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breastfeeding linked to the reduction of both rotavirus shedding and IgA levels after Rotarix® immunization in Mexican infants.
    Bautista-Marquez A; Velasquez DE; Esparza-Aguilar M; Luna-Cruz M; Ruiz-Moran T; Sugata K; Jiang B; Parashar U; Patel M; Richardson V
    Vaccine; 2016 Oct; 34(44):5284-5289. PubMed ID: 27663670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.